Name: CSTL Income Statement - Castle Biosciences Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

CSTL - Castle Biosciences Inc.

USD | NASDAQ | Healthcare

CSTL Income Statement - Castle Biosciences Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q3 FY 18	Q2 FY 18
Revenues
Revenues	83.7	87.0	83.0	86.2	88.0	86.3	85.8	87.0	73.0	66.1	61.5	50.1	42.0	38.3	37.0	34.8

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Revenues
Revenues	339.9	344.2	332.1	219.8	137.0	94.1	62.6	51.9	22.8
Cost of Revenue	75.2	71.0	60.2	45.0	32.0	15.8	9.7	7.3	5.3
Gross Profit	264.7	273.2	271.9	174.8	105.0	78.3	53.0	44.6	17.5
Operating Expenses
Research & Development	53.7	51.9	52.0	53.6	44.9	29.6	13.3	7.4	4.9
Selling General & Administrative	235.6	229.3	200.0	180.2
Operating Income
Operating Income	(33.3)	(42.8)	8.7	(68.0)	(72.9)	(40.1)	(6.5)	7.3	(3.8)
Non-Operating
Interest Income	11.2	11.8	12.9	10.6	4.0	0.1	0.4	0.3	0.0
Interest Expense	0.2	0.1	0.6	0.0	0.0
Tax & Net
Income Tax Expense	(4.8)	(5.4)	3.3	0.1	(1.8)	(8.7)	0.1	0.1	0.0
Net Income From Continuing Ops	(12.8)	(24.2)	18.2	(57.5)
Per Share
EPS Basic	(0.43)	(0.83)	0.66	(2.14)	(2.58)	(1.24)	(0.54)	0.35	(5.33)
EPS Diluted	(0.43)	(0.83)	0.62	(2.14)	(2.58)
Supplementary Data
EBITDA	(18.4)	(2.0)	24.7	(55.6)	(62.3)	(36.7)	(6.1)	7.7	(3.5)
EBIT	(33.3)	(42.8)	8.7	(68.0)	(72.9)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	14.4	13.5	13.0	12.8	12.6	11.8	12.3	14.1	13.8	13.0	12.9	13.3	14.4	11.3	10.9	11.9	10.8	9.4	7.5	6.8	5.9	4.6	3.1	2.7	2.9	3.2	1.5	1.3	1.4	1.3	1.2
Selling General & Administrative	64.9	56.7	55.9	58.1	58.6	50.0	50.5	51.1	48.5	44.1	44.6	44.7	46.8	38.4	36.6	37.5
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	3.9	8.0	1.5	1.5	29.8	10.3	1.3	1.1	3.3	7.7	0.9	0.8	2.9	7.2	0.6	0.5
Amortization of Intangibles	2.2	2.3	2.3	2.0	28.3	4.3	2.3	2.2	2.2	2.3	2.3	2.2	2.2	2.2	2.3	2.1	1.6
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Operating Income
Operating Income	(18.4)	(3.8)	(6.8)	(4.3)	(27.9)	4.1	5.1	5.0	(5.5)	(5.7)	(9.6)	(21.2)	(31.5)	(22.8)	(21.5)	(4.0)	(24.5)	(15.2)	(11.8)	(8.8)	(4.3)	(3.0)	(3.9)	(0.6)	1.0	2.6	4.4	0.6	(0.3)	(2.9)	(2.7)

Tax & Net
Income Tax Expense	0.1	(0.4)	0.1	(4.7)	(0.4)	(1.7)	6.0	(1.0)	0.0	0.0	0.0	0.0	0.0	0.1	0.0	(2.0)	0.1	(8.7)	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Net Income From Continuing Ops	(14.5)	(2.3)	(0.5)	4.5	(25.8)	9.6	2.3	8.9	(2.5)	(2.6)	(6.9)	(18.8)	(29.2)	(20.6)	(20.2)	(1.6)	(24.6)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(14.5)	(2.3)	(0.5)	4.5	(25.8)	9.6	2.3	8.9	(2.5)	(2.6)	(6.9)	(18.8)	(29.2)	(20.6)	(20.2)	(1.6)	(24.6)
Net Income Attributable To Parent	(14.5)	(2.3)	(0.5)	4.5	(25.8)	9.6	2.3	8.9	(2.5)	(2.6)	(6.9)	(18.8)	(29.2)	(20.6)	(20.2)	(1.6)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(14.5)	(2.3)	(0.5)	4.5	(25.8)	9.6	2.3	8.9	(2.5)	(2.6)	(6.9)	(18.8)	(29.2)	(20.6)	(20.2)

Per Share
EPS Basic	(0.49)	-	(0.02)	0.16	(0.90)	-	0.08	0.32	(0.09)	-	(0.26)	(0.70)	(1.10)	-	(0.77)	(0.06)	(0.97)	-	(0.47)	(0.35)	(0.17)	-	(0.23)	(0.08)	0.03	-	0.43	(1.05)	(1.22)	(2.33)	-
EPS Diluted	(0.49)	-	(0.02)	0.15	(0.90)	-	0.08	0.31	(0.09)	-	(0.26)	(0.70)	(1.10)	-	(0.77)	(0.06)	(0.97)	-
Shares Basic	29.9	-	29.1	28.9	28.6	-	27.8	27.6	27.5	-	26.8	26.7	26.6	-	26.3	26.1	25.4	-
Shares Diluted	29.9	-	29.1	29.5	28.6	-	29.4	28.7	27.5	-	26.8	26.7	26.6	-	26.3	26.1	25.4	-

Supplementary Data
EBITDA	(14.5)	4.2	(5.3)	(2.8)	1.8	14.3	6.3	6.1	(2.1)	2.1	(8.7)	(20.4)	(28.6)	(15.6)	(20.9)	(3.4)	(22.4)	(12.8)	(11.4)	(8.4)	(4.1)	(2.9)	(3.8)	(0.5)	1.1	2.7	4.5	0.7	(0.2)	(2.8)	(2.6)
EBIT	(18.4)	(3.8)	(6.8)	(4.3)	(27.9)	4.1	5.1	5.0	(5.5)	(5.7)	(9.6)	(21.2)	(31.5)	(22.8)	(21.5)	(4.0)	(24.5)	(15.2)	(11.8)